{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    8,
    12,
    13,
    14,
    15
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of BIVV001 weekly prophylaxis as estimated by the mean ABR and one-sided 97.5% CI in Arm A.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Key Secondary Efficacy Objective",
        "text": "To perform an intra-patient comparison of ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Patient Reported Outcomes Objective",
        "text": "To evaluate the effect of BIVV001 on physical health, pain intensity, and joint health",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3",
          "ep_4",
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Safety Objective",
        "text": "To assess the safety and immunogenicity of IV BIVV001",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6",
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Pharmacokinetics Objective",
        "text": "To assess the pharmacokinetics of IV BIVV001",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Exploratory Objective",
        "text": "To evaluate participants’ expectations of treatment and perception of treatment impact",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Annualized Bleeding Rate (ABR) in Arm A",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Key Secondary Efficacy Endpoint",
        "text": "Intra-patient comparison of ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Haem-A-QoL Physical Health Score",
        "text": "Change from baseline to Week 52 in Haem-A-QoL (≥17 years old) Physical Health score",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_4",
        "name": "PROMIS Pain Intensity 3a",
        "text": "Change from baseline to Week 52 in PROMIS Pain Intensity 3a",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "HJHS Total Score",
        "text": "Change from baseline to Week 52 in Hemophilia Joint Health Score (HJHS) total score",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Safety Endpoints",
        "text": "Incidence and severity of AEs, clinically significant changes in laboratory parameters, vital signs, and physical examination findings",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_7",
        "name": "Immunogenicity Endpoint",
        "text": "Incidence of inhibitor development",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_8",
        "name": "PK Parameters",
        "text": "PK parameters summarized for both the one-stage aPTT clotting assay and two-stage chromogenic assay",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_9",
        "name": "Exit Interview Endpoint",
        "text": "Participants’ expectations of treatment and perception of treatment impact assessed via exit interview",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - ABR in Arm A",
        "populationSummary": "Previously treated patients (PTPs) ≥12 years of age with severe hemophilia A (ITT/Full Analysis Set) Summary measure: Mean ABR estimated via Negative-Binomial regression with one-sided 97.5% CI.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Participant permanently discontinues study treatment before 52 weeks",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Use of non-study FVIII products",
            "text": "Use of FVIII products other than BIVV001 (except in life-threatening emergencies)",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV001 50 IU/kg IV once weekly (QW)",
        "analysisPopulation": "Previously treated patients (PTPs) ≥12 years of age with severe hemophilia A (ITT/Full Analysis Set)",
        "variableOfInterest": "Annualized Bleeding Rate (ABR)",
        "summaryMeasure": "Mean ABR estimated via Negative-Binomial regression with one-sided 97.5% CI"
      },
      {
        "id": "est_2",
        "name": "Key Secondary Efficacy Estimand - Intra-patient ABR Comparison",
        "populationSummary": "Participants in Arm A with ≥6 months study duration and ≥6 months historical prophylaxis data Summary measure: Median difference in ABR (Non-inferiority margin of 4).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Study withdrawal",
            "text": "Participant withdraws from study before completing 6 months of BIVV001 treatment",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV001 50 IU/kg IV QW vs. Historical FVIII Prophylaxis",
        "analysisPopulation": "Participants in Arm A with ≥6 months study duration and ≥6 months historical prophylaxis data",
        "variableOfInterest": "Intra-patient difference in ABR",
        "summaryMeasure": "Median difference in ABR (Non-inferiority margin of 4)"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - Physical Health Score",
        "populationSummary": "Adult patients (≥17 years old) in Arm A Summary measure: Adjusted mean change from baseline using MMRM.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of BIVV001 prior to Week 52 assessment",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV001 50 IU/kg IV QW",
        "analysisPopulation": "Adult patients (≥17 years old) in Arm A",
        "variableOfInterest": "Change from baseline to Week 52 in Haem-A-QoL Physical Health score",
        "summaryMeasure": "Adjusted mean change from baseline using MMRM"
      },
      {
        "id": "est_4",
        "name": "Secondary Efficacy Estimand - Pain Intensity",
        "populationSummary": "Participants in Arm A Summary measure: Adjusted mean change from baseline using MMRM.",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_4",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of BIVV001 prior to Week 52 assessment",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV001 50 IU/kg IV QW",
        "analysisPopulation": "Participants in Arm A",
        "variableOfInterest": "Change from baseline to Week 52 in PROMIS Pain Intensity 3a",
        "summaryMeasure": "Adjusted mean change from baseline using MMRM"
      },
      {
        "id": "est_5",
        "name": "Secondary Efficacy Estimand - Joint Health",
        "populationSummary": "Participants in Arm A Summary measure: Adjusted mean change from baseline using MMRM.",
        "analysisPopulationId": "est_5_pop",
        "variableOfInterestId": "ep_5",
        "interventionIds": [
          "est_5_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_6",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of BIVV001 prior to Week 52 assessment",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV001 50 IU/kg IV QW",
        "analysisPopulation": "Participants in Arm A",
        "variableOfInterest": "Change from baseline to Week 52 in HJHS total score",
        "summaryMeasure": "Adjusted mean change from baseline using MMRM"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 4,
      "exploratoryObjectives": 1,
      "totalEndpoints": 9,
      "totalEstimands": 5
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of BIVV001 weekly prophylaxis as estimated by the mean ABR and one-sided 97.5% CI in Arm A.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Key Secondary Efficacy Objective",
        "text": "To perform an intra-patient comparison of ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Patient Reported Outcomes Objective",
        "text": "To evaluate the effect of BIVV001 on physical health, pain intensity, and joint health",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3",
          "ep_4",
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Safety Objective",
        "text": "To assess the safety and immunogenicity of IV BIVV001",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6",
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Pharmacokinetics Objective",
        "text": "To assess the pharmacokinetics of IV BIVV001",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Exploratory Objective",
        "text": "To evaluate participants’ expectations of treatment and perception of treatment impact",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Annualized Bleeding Rate (ABR) in Arm A",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Key Secondary Efficacy Endpoint",
        "text": "Intra-patient comparison of ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Haem-A-QoL Physical Health Score",
        "text": "Change from baseline to Week 52 in Haem-A-QoL (≥17 years old) Physical Health score",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_4",
        "name": "PROMIS Pain Intensity 3a",
        "text": "Change from baseline to Week 52 in PROMIS Pain Intensity 3a",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "HJHS Total Score",
        "text": "Change from baseline to Week 52 in Hemophilia Joint Health Score (HJHS) total score",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Safety Endpoints",
        "text": "Incidence and severity of AEs, clinically significant changes in laboratory parameters, vital signs, and physical examination findings",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_7",
        "name": "Immunogenicity Endpoint",
        "text": "Incidence of inhibitor development",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_8",
        "name": "PK Parameters",
        "text": "PK parameters summarized for both the one-stage aPTT clotting assay and two-stage chromogenic assay",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_9",
        "name": "Exit Interview Endpoint",
        "text": "Participants’ expectations of treatment and perception of treatment impact assessed via exit interview",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - ABR in Arm A",
        "populationSummary": "Previously treated patients (PTPs) ≥12 years of age with severe hemophilia A (ITT/Full Analysis Set) Summary measure: Mean ABR estimated via Negative-Binomial regression with one-sided 97.5% CI.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Participant permanently discontinues study treatment before 52 weeks",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Use of non-study FVIII products",
            "text": "Use of FVIII products other than BIVV001 (except in life-threatening emergencies)",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV001 50 IU/kg IV once weekly (QW)",
        "analysisPopulation": "Previously treated patients (PTPs) ≥12 years of age with severe hemophilia A (ITT/Full Analysis Set)",
        "variableOfInterest": "Annualized Bleeding Rate (ABR)",
        "summaryMeasure": "Mean ABR estimated via Negative-Binomial regression with one-sided 97.5% CI"
      },
      {
        "id": "est_2",
        "name": "Key Secondary Efficacy Estimand - Intra-patient ABR Comparison",
        "populationSummary": "Participants in Arm A with ≥6 months study duration and ≥6 months historical prophylaxis data Summary measure: Median difference in ABR (Non-inferiority margin of 4).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Study withdrawal",
            "text": "Participant withdraws from study before completing 6 months of BIVV001 treatment",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV001 50 IU/kg IV QW vs. Historical FVIII Prophylaxis",
        "analysisPopulation": "Participants in Arm A with ≥6 months study duration and ≥6 months historical prophylaxis data",
        "variableOfInterest": "Intra-patient difference in ABR",
        "summaryMeasure": "Median difference in ABR (Non-inferiority margin of 4)"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - Physical Health Score",
        "populationSummary": "Adult patients (≥17 years old) in Arm A Summary measure: Adjusted mean change from baseline using MMRM.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of BIVV001 prior to Week 52 assessment",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV001 50 IU/kg IV QW",
        "analysisPopulation": "Adult patients (≥17 years old) in Arm A",
        "variableOfInterest": "Change from baseline to Week 52 in Haem-A-QoL Physical Health score",
        "summaryMeasure": "Adjusted mean change from baseline using MMRM"
      },
      {
        "id": "est_4",
        "name": "Secondary Efficacy Estimand - Pain Intensity",
        "populationSummary": "Participants in Arm A Summary measure: Adjusted mean change from baseline using MMRM.",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_4",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of BIVV001 prior to Week 52 assessment",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV001 50 IU/kg IV QW",
        "analysisPopulation": "Participants in Arm A",
        "variableOfInterest": "Change from baseline to Week 52 in PROMIS Pain Intensity 3a",
        "summaryMeasure": "Adjusted mean change from baseline using MMRM"
      },
      {
        "id": "est_5",
        "name": "Secondary Efficacy Estimand - Joint Health",
        "populationSummary": "Participants in Arm A Summary measure: Adjusted mean change from baseline using MMRM.",
        "analysisPopulationId": "est_5_pop",
        "variableOfInterestId": "ep_5",
        "interventionIds": [
          "est_5_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_6",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of BIVV001 prior to Week 52 assessment",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV001 50 IU/kg IV QW",
        "analysisPopulation": "Participants in Arm A",
        "variableOfInterest": "Change from baseline to Week 52 in HJHS total score",
        "summaryMeasure": "Adjusted mean change from baseline using MMRM"
      }
    ]
  }
}